| Literature DB >> 33671213 |
Alessio Ardizzone1, Roberta Fusco1, Giovanna Casili1, Marika Lanza1, Daniela Impellizzeri1, Emanuela Esposito1, Salvatore Cuzzocrea1,2.
Abstract
Palmitoylethanolamide (PEA), a fatty acid amide, has been widely investigated for its analgesic and anti-inflammatory properties. The ultra-micronized formulation of PEA (um-PEA), that has an enhanced rate of dissolution, is extensively used. Acetyl-l-carnitine (LAC), employed for the treatment of neuropathic pain in humans, is able to cause analgesia by up-regulating type-2 metabotropic glutamate (mGlu2) receptors. In the present study, we tested different associations of um-PEA, LAC and non-micronized PEA (non-m-PEA) in a rat model of carrageenan (CAR)-induced paw edema. Intraplantar injection of CAR into the hind paw of animals caused edema, thermal hyperalgesia, accumulation of infiltrating inflammatory cells and augmented myeloperoxidase (MPO) activity. All these parameters were decreased in a significantly manner by oral administration of a compound constituted by a mixture of um-PEA and LAC in relation 1:1 (5 mg/kg), but not with the association of single compounds administered one after the other. These findings showed the superior anti-inflammatory and anti-nociceptive action displayed by oral administration of um-PEA and LAC versus LAC plus, separate but consecutive, um-PEA in the rat paw CAR model of inflammatory pain.Entities:
Keywords: acetyl-l-carnitine (LAC); carrageenan (CAR); edema; inflammatory pain; palmitoylethanolamide (PEA)
Mesh:
Substances:
Year: 2021 PMID: 33671213 PMCID: PMC7922157 DOI: 10.3390/ijms22041967
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923